Drugs / JTE-451
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03018509 | Dec 2016 → Jun 2017 | psoriasis | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03832738 | Jan 2019 → Mar 2020 | psoriasis | Akros Pharma Inc. | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTE-451 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03018509 ↗ |